WELLINGTON, New Zealand, March 3, 2025 — Volpara Health, a global leader in AI-powered breast health solutions and a subsidiary of Lunit, today announced three major milestones:
- Craig Hadfield, Volpara’s Chief Customer and Financial Officer, will become CEO on April 1, succeeding Teri Thomas as she pursues her next career steps.
- Volpara density is now a validated input to the BOADICEA breast cancer risk model.
- A record of 21 independent abstracts featuring Lunit and Volpara solutions were presented at ECR 2025.
CEO transition
Teri Thomas, who has led Volpara since 2022, played a key role in the company’s transformation, strengthening its AI platform and overseeing its 2024 acquisition by Lunit. Under her leadership, the company grew annual recurring revenue to over $34 million.
“We deeply appreciate Teri’s leadership and impact,” said Hadfield. “She has positioned Volpara for continued success, and we wish her well in her next phase.”
Reflecting on her tenure, Teri stated, “It’s been an honor to lead Volpara and work with an incredible team advancing AI-driven breast health solutions. While I’m excited for my next chapter, I remain a strong supporter of Volpara’s mission.”
Hadfield has been instrumental in Volpara’s financial growth, SaaS transition, and strategic acquisitions. “I’m honored to lead Volpara into its next phase of innovation and impact,” said Craig. “I look forward to working with our team, partners, and customers to advance breast health.”
Volpara density now integrated into BOADICEA breast cancer risk model
Volpara volumetric breast density assessment is now a validated input to the newly released version of the BOADICEA breast cancer risk model. This marks a significant milestone, as Volpara density is now integrated into two different breast cancer risk models named in the NCCN guidelines—Tyrer-Cuzick, and BOADICEA, sometimes referred to as CanRisk, its web application.
Any Volpara customers can use their Volpara density information via CanRisk today. CanRisk is endorsed by international societies and guidelines for use in Australia, the EU, the UK, and Canada. Studies have shown the use of Volpara density in BOADICEA to improve model accuracy compared to using BI-RADS density categories, enhancing breast cancer risk assessment capabilities for healthcare providers worldwide.
A record-high 21 Lunit and Volpara research abstracts at ECR 2025
At ECR 2025, Lunit and Volpara’s solutions were featured in a record-high 21 independent research abstracts. This milestone highlights the growing impact of AI-driven breast health solutions in the global radiology community, reinforcing Volpara’s and Lunit’s commitment to advancing cancer detection and patient care through innovation and scientific research.
# # #
Media Contact:
Andrew Thompson-Young
Clarity Quest
Andrew@Clarityqst.com
877-887-7611
